The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12-2 on March 29, 2016 that the benefits of Nuplazid for the treatment of Parkinson's Disease Psychosis outweigh the associated risks. The Advisory Committee provides the FDA with independent recommendations from expert; the FDA is not bound by the Committee's recommendations but considers the Committee's finding during the new drug review process. Updated June 2016 Cost Of Nuplazid The cost of … [Read more...] about Nuplazid Drug Could Be A Game Changer For Parkinson’s Disease